Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
about
Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy.Role of MSC-derived galectin 3 in the AML microenvironment.The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.Inhibition of MEK, a canonical KRAS pathway effector in mutant NSCLC
P2860
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@en
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@nl
type
label
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@en
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@nl
prefLabel
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@en
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@nl
P2093
P2860
P1433
P1476
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.
@en
P2093
David A Cheresh
Erika Cosset
Hiromi I Wettersten
Jacqueline Lesperance
Jay S Desgrosellier
Kathryn C Elliott
Laetitia Seguin
Maria F Camargo
Sara M Weis
Shumei Kato
P2860
P356
10.1158/2159-8290.CD-17-0539
P577
2017-09-11T00:00:00Z